Worth reading
41Recurring
Scored from 4 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
20000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Issuance of share acquisition rights as stock options
Who receives how much
20,000 shares of the Company's common stock (200 share acquisition rights, 100 shares per right)
2 employees of the Company's subsidiary: 200 rights (20,000 shares)
The lower thin line represents the existing number of shares to which these shares will be added.
The stock acquisition rights will be issued at no cost. The exercise price is ¥1,000 per share.
Terms of the stock acquisition rights
Exercise price
The initial exercise price is ¥1,000 per share. Whether a revision clause applies and the floor for any revision: Not disclosed
Exercise period
From 1 August 2030 to 31 July 2032
Number of Stock Acquisition Rights
Total number to be issued: 200 rights. Number of outstanding unexercised rights: Not disclosed
Categories and Number of Persons Covered
2 employees of the Company's subsidiary, 200 rights (20,000 shares)
Payment date
No monetary payment is required in exchange for the stock acquisition rights.
Procedures under the Corporate Code of Conduct
Approved at the Company's 27th Annual General Meeting of Shareholders held on 24 June 2026
Most recent equity financing
22 July 2026: The Company issued the Stem Cell Institute Co., Ltd. Series 1 Stock Acquisition Rights and Stem Cell Institute Co., Ltd. Series 2 Stock Acquisition Rights to the Company's directors and employees
| Item | Details |
|---|---|
| Type of issuance or disposal | Issuance of share acquisition rights as stock options |
| Number of shares to be issued or disposed of | 20,000 shares of the Company's common stock (200 share acquisition rights, 100 shares per right) |
| Issue price and disposal price | The stock acquisition rights will be issued at no cost. The exercise price is ¥1,000 per share. |
| Payment date | No monetary payment is required in exchange for the stock acquisition rights. |
| Intended allottee | 2 employees of the Company's subsidiary: 200 rights (20,000 shares) |
| Exercise price | The initial exercise price is ¥1,000 per share. Whether a revision clause applies and the floor for any revision: Not disclosed |
| Exercise period | From 1 August 2030 to 31 July 2032 |
| Number of Stock Acquisition Rights | Total number to be issued: 200 rights. Number of outstanding unexercised rights: Not disclosed |
| Categories and Number of Persons Covered | 2 employees of the Company's subsidiary, 200 rights (20,000 shares) |
| Procedures under the Corporate Code of Conduct | Approved at the Company's 27th Annual General Meeting of Shareholders held on 24 June 2026 |
| Most recent equity financing | 22 July 2026: The Company issued the Stem Cell Institute Co., Ltd. Series 1 Stock Acquisition Rights and Stem Cell Institute Co., Ltd. Series 2 Stock Acquisition Rights to the Company's directors and employees |
Items this document does not state (17)
Total issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To motivate and boost the morale of the Company's and its subsidiaries' directors and employees toward improving business performance, secure talented personnel, and contribute to increasing the corporate value of the Group as a whole.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.